Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer

Citation
A. Latil et al., Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer, PROSTATE, 40(4), 1999, pp. 225-231
Citations number
39
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
PROSTATE
ISSN journal
02704137 → ACNP
Volume
40
Issue
4
Year of publication
1999
Pages
225 - 231
Database
ISI
SICI code
0270-4137(19990901)40:4<225:EAMAOT>2.0.ZU;2-Q
Abstract
BACKGROUND, Loss of heterozygosity (LOH) on chromosome arm 18q is common in sporadic prostate cancer and may be involved in cancer development through inactivation of tumor-suppressor genes (TSG). Recent identification, at 18 q21.1, of MADX2/Smad2, a key component in transforming growth factor beta ( TGF beta)-family signaling pathways, led us to investigate the role of this gene in prostate tumorigenesis. METHODS. Sporadic primary prostate tumors from 25 patients with clinically localized tumors and 7 with metastatic forms were examined for MADX2/Smad2 mutations by using polymerase chain reaction-single-strand conformational p olymorphism (PCR-SSCP) analysis of cDNA, and for gene expression by quantit ative reverse transcription-polymerase chain reaction (RT-PCR). RESULTS. We detected no mutation in MADX2/Smad2 and no abnormal mRNA expres sion. CONCLUSIONS. Despite recent evidence indicating that MADR2/Smad2 acts as a tumor-suppressor gene, our findings suggest a limited role of this gene in prostate tumorigenesis, at least in the early stages. Another key tumor-sup pressor gene may therefore be the main target of the observed LOH at 18q21. 1. (C) 1999 Wiley-Liss, Inc.